Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review with Therapeutic Drugs Profile – H2 2017

Albany, New York, July 26, 2017: Cognitive impairment associated with schizophrenia (CIAS) show various symptoms which have a very negative impact on the patients’ quality of life and ability to function. The treatment of this disorder include antipsychotic medications that mark the need of the medicine as a must, and hence its therapeutic development is required to lead a normal life. To discuss in detail, Market Research Hub (MRH) has lately added a pipeline review titled as “Cognitive Impairment Associated with Schizophrenia (CIAS) – Pipeline Review, H2 2017” to its vast report repository. The pipeline review, H2 2017, provides an in-depth assessment of the cognitive impairment associated with schizophrenia (CIAS) (Central Nervous System) pipeline landscape that helps in determining the global therapeutic landscape of CIAS.

Request Free Sample Report:

The symptom of CIAS includes poor executive functioning, inability to sustain attention and problems with working memory.  The CIA (Central Nervous System) pipeline enhances the decision-making capabilities and creates effective counter strategies of the potential new clients to gain competitive advantage. Moreover, the pipeline review will help in classifying potential new clients or partners in the target demographic. It develops tactical initiatives by understanding the focused areas of leading companies, and further plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

The research commences with the global report coverage that includes CIAS overview, CIAS therapeutic development with complete analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Furthermore, the companies involved in the therapeutic development are also featured that include AbbVie Inc., Amarantus Bioscience Holdings Inc., Astellas Pharma Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Coronis NeuroSciences Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., H. Lundbeck A/S, Heptares Therapeutics Ltd., Intra-Cellular Therapies Inc., Iproteos SL, Luc Therapeutics Inc., Neuralstem Inc., Pfizer Inc., Sage Therapeutics Inc., Saniona AB, SK Biopharmaceuticals Co Ltd., Spherium Biomed SL, Suven Life Sciences Ltd., Takeda Pharmaceutical Company Ltd. and Vanda Pharmaceuticals Inc.

Browse Full Report With TOC:

The pipeline review further includes the therapeutic drugs assigned for the CIAS and conclude with the dormant projects, discontinued products, product development milestone and finally with featured news and press releases. The various drug profiles featured are; A-431404, AN-761, AQW-051, ASP-4345, ASP-5736, AUT-1, AUT-6, AUT-9, AVL-3288, basmisanil, BMS-955829, CP-102 and other. This concludes the intelligently accessed pipeline review related to cognitive impairment associated with schizophrenia and describes the various therapeutic development of related medicated drugs.

Make An Enquiry:


About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 866-997-4948 (US-Canada)


Read Industry News At:

Designed by
Powered by
%d bloggers like this: